FDA
-
-
-
-
-
-
-
Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome
-
-
-
-
-
-
-
Medicus Pharma reports positive dose response in skin cancer trial
-
-
-
-
-
-
-
Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome
-
-
-
-
-
-
-
Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate
-
-
-
-
-
-
-
Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webca
-
-
-
-
-
-
-
Medicus Pharma on Bloomberg World
-
-
-
-
-
-
-
Medicus Pharma study shows stable bone turnover with hormone suppression
-
326,531 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

